Adage Capital Partners
CTNM

Adage Capital Partners’s Contineum Therapeutics CTNM Stock Holding History

Adage Capital Partners’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-200,000
Closed -$2.93M – 956
2024
Q4 		$2.93M Hold
200,000
– – 0.01% 768
2024
Q3 		$3.83M Sell
200,000
-95,000
-32% -$1.82M 0.01% 739
2024
Q2 		$5.19M Buy
+295,000
New +$4.75M 0.01% 710

Other funds holding CTNM

JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return

Adage Capital Partners's CTNM Position: Q1 2025 in Review

Adage Capital Partners sold out of Contineum Therapeutics (CTNM) in Q1 2025, closing a stake of 200,000 shares — an estimated $2.93M sold.

Adage Capital Partners first reported a position in CTNM in Q2 2024 and held it in 3 quarters. The position peaked at $5.19M in Q2 2024. 63 funds tracked by Wall St. Rank hold CTNM as of Q1 2025.

  • Adage Capital Partners reported no remaining Contineum Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Adage Capital Partners sold 200,000 Contineum Therapeutics shares in Q1 2025, an estimated $2.93M.
  • Adage Capital Partners first reported a position in Contineum Therapeutics in Q2 2024 and held it in 3 quarters.
  • Adage Capital Partners's Contineum Therapeutics position peaked at $5.19M in Q2 2024.
  • 63 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2025.

Based on Adage Capital Partners's 13F filing for Q1 2025, filed 15 May 2025.